Literature DB >> 23219953

Complex regional pain syndrome, prototype of a novel kind of autoimmune disease.

Andreas Goebel1, Franz Blaes.   

Abstract

Complex regional pain syndrome (CRPS) is a painful condition, which arises in a limb after trauma. CRPS can profoundly affect patients' quality of life, and there is no cure. CRPS is associated with limb-confined sensory, motor, skin, bone and autonomic abnormalities. Recent research has shown that some patients respond to treatment with immunoglobulins, and that a majority have IgG serum-autoantibodies directed against, and activating autonomic receptors. CRPS serum-IgG, when transferred to mice elicits abnormal behaviour. These results suggest that CRPS is associated with an autoantibody-mediated autoimmune process in some cases. CRPS has unusual features, including a non-destructive, and regionally-confined course. We propose that CRPS constitutes a prototype of a new kind of autoimmunity, which we term 'IRAM' (injury-triggered, regionally-restricted autoantibody-mediated autoimmune disorder with minimally-destructive course). Understanding autoimmune contribution to CRPS should allow the exploration of novel treatment modalities in the future. Additional 'functional' disorders, painful or painless may be autoimmune in nature.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219953     DOI: 10.1016/j.autrev.2012.10.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  36 in total

Review 1.  Complex Regional Pain Syndrome, Current Concepts and Treatment Options.

Authors:  Ivan Urits; Abra H Shen; Mark R Jones; Omar Viswanath; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2018-02-05

2.  Immune activation and autoimmunity in chronic pain conditions and response to immunoglobulin G.

Authors:  A Goebel
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 3.  Mechanism-based treatment in complex regional pain syndromes.

Authors:  Janne Gierthmühlen; Andreas Binder; Ralf Baron
Journal:  Nat Rev Neurol       Date:  2014-08-19       Impact factor: 42.937

4.  Autoantibodies against P29ING4 are associated with complex regional pain syndrome.

Authors:  N T Baerlecken; R Gaulke; N Pursche; T Witte; M Karst; M Bernateck
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

5.  Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.

Authors:  Øystein Fluge; Olav Mella; Ove Bruland; Kristin Risa; Sissel E Dyrstad; Kine Alme; Ingrid G Rekeland; Dipak Sapkota; Gro V Røsland; Alexander Fosså; Irini Ktoridou-Valen; Sigrid Lunde; Kari Sørland; Katarina Lien; Ingrid Herder; Hanne Thürmer; Merete E Gotaas; Katarzyna A Baranowska; Louis Mlj Bohnen; Christoph Schäfer; Adrian McCann; Kristian Sommerfelt; Lars Helgeland; Per M Ueland; Olav Dahl; Karl J Tronstad
Journal:  JCI Insight       Date:  2016-12-22

6.  Spontaneous onset of complex regional pain syndrome Type I in a woman infected with Bartonella koehlerae.

Authors:  Cristina Pérez Vera; Ricardo G Maggi; Christopher W Woods; Patricia E Mascarelli; Edward B Breitschwerdt
Journal:  Med Microbiol Immunol       Date:  2013-12-10       Impact factor: 3.402

Review 7.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 8.  New Concepts in Complex Regional Pain Syndrome.

Authors:  Maral Tajerian; John David Clark
Journal:  Hand Clin       Date:  2016-02       Impact factor: 1.907

9.  Autoimmunity contributes to nociceptive sensitization in a mouse model of complex regional pain syndrome.

Authors:  Wen-Wu Li; Tian-Zhi Guo; Xiaoyou Shi; Eva Czirr; Trisha Stan; Peyman Sahbaie; Tony Wyss-Coray; Wade S Kingery; J David Clark
Journal:  Pain       Date:  2014-09-10       Impact factor: 6.961

Review 10.  From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain.

Authors:  Theodore J Price; Michael S Gold
Journal:  Pain Med       Date:  2018-08-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.